The Clinical Feature of Chronic Hepatitis B Patients with High HBV pgRNA
Journal Title: Diseases & Research - Year 2023, Vol 3, Issue 1
Abstract
ackground and Aims At present, nucleos(t)ide analogue (NA) is usually used to treat chronic hepatitis B, but there are still some patients with high levels of pgRNA after long-term treatment. We tried to study the clinical characteristics of this part of the population. Methods A total of 211 patients who had been treated with NAs for more than one year and had been followed up in our outpatient department for a long time were included in the study. The concentrations of HBV serological (HBsAg, HBeAg, HBV DNA, anti-HBe) /biochemical indicators (ALT, AST, GGT, AFP) were measured in this study. Results ALT/AST/HBV DNA/HBsAg in high pgRNA group was significantly higher than those in low pgRNA group, and the HBeAg negative rate of high pgRNA group was much lower than that of low pgRNA group. Conclusion CHB patients with high pgRNA are more likely to have relatively active viruses and more severe liver inflammation. In addition, in terms of virological response, the proportion of HBeAg negative in high pgRNA population is significantly higher than that in low pgRNA population, and the titer of HBsAg is significantly higher than that of people with low pgRNA.
Authors and Affiliations
Yunzhe Zhang, Xuezhong Lei
Keywords
Related Articles
- EP ID EP740139
- DOI 10.54457/DR.202301001
- Views 33
- Downloads 0
ADAMTS Proteases: Their Multifaceted Role in the Regulation of Cancer Metastasis
Cancer leads to nearly 10 million deaths worldwide per year. The tumour microenvironment (TME) is fundamental for tumour growth and progression. A key component of the TME, the extracellular matrix (ECM) has recently bec...
Roles of Toll-like Receptor 3 in Intrauterine Transmission of Hepatitis B Virus in Mothers with High Viral Load
Backgrounds Despite passive and active immunization, perinatal mother-to-infant transmission (MTIT) of hepatitis B virus (HBV) still occurs in women with high levels of viremia. Thus, understanding the mechanisms of MTIT...
Tumour Microenvironment in Therapy of Metastatic Cancer
GLOBOCAN 2020 has reported that the global cancer burden is 19.3 million cases, with 10 million deaths[1]. The overall survival (OS) after treatment with innovative cancer therapies has not changed for most metastatic ca...
Significance of Liquid Biopsy Containing Circulating Tumor DNA (ctDNA) Analysis for Evaluation and Management of Metastatic Cancer
According to the GLOBOCAN 2020 data from WHO, nearly 10 million deaths took place due to cancer thus, cancer became a leading cause of death all over the world. The most common cancer are breast cancer, lung cancer, colo...
Plasma Exchange to Treat Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome after Anti-CD19 Chimeric Antigen Receptor-T Cell Infusion: A Case Report
Adoptive cell immunotherapy with chimeric antigen receptor-T (CAR-T) cells has shown remarkable clinical out-comes. However, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICA...